Imaging drug to find prostate cancer spread before or after treatment
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an imaging agent that helps find cancer that has spread beyond the prostate, either when first diagnosed or if it comes back after treatment. The goal is to see what dose works best for clear pictures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that is high-risk (newly diagnosed) or has returned after treatment (biochemical recurrence).
- You are willing to get an anti-anxiety pill before the scan if you are claustrophobic.
- You are willing to use two effective birth control methods for 7 days after the imaging dose (if sexually active).
- Your kidney, liver, and blood cell counts must be in an acceptable range as per tests.
- You have not had certain recent imaging tests or treatments for cancer, and you are not planning other prostate cancer procedures during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
This study tests a new imaging method (PET scan) that uses a special tracer to find prostate cancer cells, whether it's the first diagnosis or a recurrence after treatment. The goal is to see how well this imaging works for locating cancer in the body.
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
This trial tests a new imaging drug that may help your doctor see the exact location of prostate cancer using a PET scan. The imaging is done before surgery to remove the prostate or, if you have recurrence, to find where the cancer has returned.
This trial tests a new radioactive tracer called ELI421 to see how well it works for PET imaging in people with prostate cancer. It may help doctors find cancer more clearly.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.